ecrin-mdr-crcClinical2012Metastatic Colorectal CancerColorectal NeoplasmsMetastatic Colorectal CancerColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2149874France10Cross overAfatinibChemotherapy refractoryWtKRAS metastatic colorectal cancerCetuximabECRIN MDRCompletedfalseDual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal CancerThis is a multicentric, phase II and open label study.75 patients are expected to be randomized in 35 centers. The main objective is to assess the efficacy and safety of Afatinib -cetuximab combo versus cetuximab alone in treatment of patients with refractory wtKRAS metastatic colorectal cancer.2012-10-152149874NCT01919879